NicOx appoints Pascal Pfister MD as Chief Scientific Officer and strengthens R&D organization

03-Jul-2007

NicOx S.A. announced the appointment of Pascal Pfister MD as Chief Scientific Officer (CSO). In this role Dr. Pfister will report to Michele Garufi, Chairman and CEO, and will have overall responsibility for NicOx' Research and Development (R&D) activities, notably the Research, regulatory affairs, Clinical Development and drug development Departments. Dr. Pfister will bring extensive experience and leadership to NicOx from his 19 year career at Novartis and Sandoz.

NicOx has also further strengthened its R&D team through the appointment of Jacques DjianMD as Cardiometabolic Area Leader, who will advise and manage NicOx' R&D in the cardiometabolic disease area.

Dr. Pfister's previous management career includes 19 years at Novartis & Sandoz Pharmaceuticals in France, Switzerland and in the US, where he has occupied positions of growing responsibility in a range of therapeutic fields, including the inflammatory and cardiometabolic disease areas. His most recent position was Vice President, Global Therapeutic Area Head for Respiratory & Dermatology, Clinical Development & Medical Affairs where he was responsible for managing a large team across Europe, the United Kingdom and the US.

He has successfully participated in the development and subsequent launch and marketing of several brands. Dr. Pfister was also actively involved in the optimization of the late stage development plans for Starlix® for the treatment of type 2 diabetes and Prexige®, a COX-2 Inhibitor for the treatment of osteoarthritis and other products in the field of dermatology (Elidel®) and transplantation (Myfortic® and Certican®). Pascal Pfister is a Medical Doctor, who graduated from the Necker School of Medicine of the University René Descartes in Paris and he also holds a diploma in pharmaceutical medicine. Prior to joining the Pharmaceutical Industry, Dr. Pfister held a post-doctoral position where he studied drugs that affect lipid metabolism at the Clinical Research Institute of Montreal, Canada.

Dr. Djian comes to NicOx with 16 years of experience in the pharmaceutical industry and was previously the Senior Scientific Consultant for Cardiovascular and Metabolic Disease issues at Novartis. Dr. Djian has also worked for Wyeth Research as Global Senior Director of the Cardiovascular Area and at Sanofi, where he was Scientific Director of Clinical Development. He has successfully participated in the development of the antihypertensive drug Aprovel® (irbesartan) and the anti-platelet agent Plavix® (clopidogrel). Jacques Djian is a Medical Doctor and graduated from the University of Paris. He has also been a practicing cardiologist at Saint-Joseph Hospital in Paris.

https://www.bionity.com/en/news/65870/nicox-appoints-pascal-pfister-md-as-chief-scientific-officer-and-strengthens-r-d-organization.html